Top Back to top

GvHD Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the CMWP of the EBMT.

Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205662
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Chronic Myeloid Leukaemia (CML)
Myelodysplastic (MDS) or MDS/MPN
Myeloproliferative Neoplasm (MPN)
Short title:
 
Primary objective:
 
Key inclusion criteria:
 
Country:
All EBMT member countries
Principal investigator:
Thomas Luft
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwpebmt@lumc.nl
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results